Holen Sie sich die Stockscreener-App
0.829
1.98%
0.025
AEON Biopharma Inc. Aktie (AEON) Neueste Nachrichten
What drives AEON Biopharma Inc. stock priceRapidly growing investment returns - Autocar Professional
Is AEON Biopharma Inc. a good long term investmentHigh-yield capital appreciation - Autocar Professional
AEON Biopharma Inc. Stock Analysis and ForecastRapid growth opportunities - jammulinksnews.com
why aeon biopharma inc. stock attracts strong analyst attentionFree Investment Community - Newser
What analysts say about AEON Biopharma Inc. stockDynamic portfolio growth - jammulinksnews.com
what makes aeon biopharma inc. stock price move sharplyROI Focused Stock Calls - Newser
Why AEON Biopharma Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
What makes AEON Biopharma Inc. stock price move sharplyFree Access to Investment Community - Newser
How AEON Biopharma Inc. stock performs during market volatilitySmart Return Focused Trading - Newser
AEON Biopharma (NASDAQ:AEON) Trading Down 10.2% – Should You Sell? - Defense World
AEON Biopharma Holds Annual Stockholders Meeting - TipRanks
AEON Biopharma, Inc. (NASDAQ:AEON) Short Interest Update - Defense World
AEON Biopharma Soars 13.67% on CEO Appointment, Talent Grants - AInvest
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma Expands Team with 100K+ Stock Awards: Inside the Biotech's Latest Hiring Move - Stock Titan
Aeon Biopharma Reports Positive Q1 2025 Earnings - TipRanks
AEON Biopharma Releases New Corporate Presentation - TipRanks
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 - The Manila Times
AEON Biopharma to Present Corporate Overview at Aegis Capital Corp. 2025 Virtual Conference - Nasdaq
AEON Biopharma Unveils Next-Gen Botulinum Toxin Therapies: CEO Details Multi-Indication Pipeline - Stock Titan
AEON Biopharma Advances Biosimilar Product Development and Appoints New CEO - Nasdaq
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
New AEON CEO Targets $3.3B Botox Market with FDA-Ready Biosimilar Development Plan - Stock Titan
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Tuesday - Defense World
Closing Bell Recap: AEON Biopharma Inc (AEON) Ends at 0.75, Reflecting a -11.76 Downturn - DWinneX
AEON Biopharma Inc (AMEX: AEON) Stock: Investors Need To Know This - Stocksregister
Is AEON Biopharma Inc’s (AMEX:AEON) Stock On The Decline? - Stocksregister
AEON Biopharma gets NYSE American nod for compliance plan - Investing.com Australia
AEON Biopharma gets NYSE American nod for compliance plan By Investing.com - Investing.com Canada
AEON Biopharma Says NYSE American Accepts Plan to Regain Compliance - marketscreener.com
AEON Biopharma Receives Acceptance from NYSE American to Regain Compliance with Listing Standards - Nasdaq
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
NYSE American Grants AEON Biopharma 2-Year Lifeline to Meet Listing Requirements - Stock Titan
4.74%
0.14%
Kapitalisierung:
|
Volumen (24h):